Teva: Feeling the Weight of Generic Competition
Profits from Teva's flagship drug, Copaxone, may be in jeopardy. The company just lost a major court case, invalidating a key patent, that will allow generic versions of the multiple sclerosis drug to market by May 2014, a full 16 months early. In this video, Motley Fool health-care analyst David Williamson discusses just how much this compressed timeline is going to hurt Teva and what he'll be looking for with the company going forward.
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.
The article Teva: Feeling the Weight of Generic Competition originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Momenta Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.